Latest News about BGNE
Recent news which mentions BGNE
From Benzinga
 
   Why Are BeiGene Shares Trading Lower Today
   
  
  
  July 11, 2023
  From Benzinga
 From Benzinga
 
   Why This BeiGene Analyst Slashes Forecast By Almost 42%
   
  
  
  June 30, 2023
  From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
   
  
  
  June 15, 2023
  From Benzinga
 
   Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
   
  
  
  May 25, 2023
  From Benzinga
 
   Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
   
  
  
  May 22, 2023
  From Benzinga
 
   What's Going On With Immix Biopharma Stock Today
   
  
  
  May 03, 2023
  From Benzinga
 
   3 Top Biotech Stocks Defying the Bear Market
   
  
  
  April 25, 2023
  From Motley Fool
 
   7 Biotech Stocks That Could Cure Your Portfolio Woes
   
  
  April 19, 2023
  Tags
   BMRN
   NASDAQ:BGNE,NASDAQ:INCY,NASDAQ:BMRN,NASDAQ:ARGX,NASDAQ:UTHR,NASDAQ:TECH,NASDAQ:LEGN
   Market News
  
  From InvestorPlace
 From Benzinga
 
   Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
   
  
  
  April 11, 2023
  From Benzinga
 
   Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
   
  
  
  April 11, 2023
  From Benzinga
 
   Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
   
  
  
  April 11, 2023
  From Benzinga
 
   Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
   
  
  
  March 13, 2023
  From Benzinga
 
   Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
   
  
  
  February 27, 2023
  From Benzinga
 
   Is Johnson & Johnson Still a Good Dividend Stock to Buy?
   
  
  
  January 26, 2023
  From Motley Fool
 From Benzinga
 
   FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
   
  January 20, 2023
  Tickers 
   BGNE
  
  
  From Benzinga
 
   One of the greatest cancer drugs ever has suddenly lost its edge. This is why it was vulnerable.
   
  
  
  January 18, 2023
  From MarketWatch
 From MarketWatch
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.